Study confirms AI outperforms conventional methods for prostate cancer ECE

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A study recently published in BJUI Compass found that Unfold AI, an FDA-cleared artificial intelligence algorithm developed by Avenda Health, accurately predicted extracapsular extension risk (ECE) and outperformed conventional methodologies.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Credit: Jonah Elkowitz/ShutterstockThat President Biden was diagnosed with prostate cancer is certainly unfortunate news, but it should come as no surprise. One in eight men in the U.S. will be told they have prostate cancer at some point in their lifetime: more than 300,000 new diagnoses occur annually, and the absolute numbers are rising. 
The National Institute for Health Care Management Foundation is now accepting letters of inquiry for the 2025-2026 funding cycle of NIHCM Foundation’s Research Grant program. We will be awarding a total of $500,000 in grants to support innovative, independent, investigator-initiated research that has the potential to inform managed care organizations, policymakers, and related stakeholders to improve the affordability and quality of U.S. health care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login